Background: The human immune system is based on a lively exchange of information between the cells, allowing for a coordinated response to germs or pathologically modified cells. This process requires the DNA information contained in the cells to be read and this is often regulated by so-called "epigenetic" processes (i.e. via the "degree of packaging" of the DNA). Special enzymes, the family of so-called histone deacetylases (HDACs), play an important role in this process. In total there are 18 different HDACs. They determine the "degree of packaging", that is to say how efficiently the information can be read.
If the "degree of packaging" is lessened, it is easier to read the DNA, and this controls the expression of a large number of proteins. In addition to this, HDACs can also regulate the activity and function of proteins. This then leads to an increase in cell activity and boosts communication between the immune cells. In the immune system, increased cell activity during an immune response is primarily manifested by an increase in the number of special immune defence cells, T-cells (or T-lymphocytes). The extent of an immune response is thereby regulated by the HDAC family.
In a study funded by the EU and FWF, researchers from MedUni Vienna – who came not only from the Division of Immunobiology at the Institute of Immunology (Wilfried Ellmeier) but also the Department of Medicine III (Rheumatology/lead author Lisa Göschl, and Michael Bonelli and Günter Steiner), Center for Anatomy and Cell Biology (Christian Seiser's group) and CeMM (Christoph Bock's group) – have shown that mice who have had HDAC1 switched off in the T-cells using a "molecular trick", do not develop experimental autoimmune encephalomyelitis (EAE) , even when the disease is artificially provoked. EAE is an autoimmune disease which can be regarded as similar to MS in the animal model – even though there are certain differences. The results of the study have now been published in the "Journal of Autoimmunity". "However, we still do not know the underlying mechanism responsible for this protective effect," explains Wilfried Ellmeier, "We now want to conduct follow-on studies to discover the molecular details."
Certain broad-spectrum HDAC molecule inhibitors are used in the treatment of patients with certain types of cancer. They are used to directly attack the tumour – and in most cases the tumour shrinks. Many preclinical studies using an animal model suggest that HDAC inhibitors could also be effective in diseases of the immune system, like autoimmune diseases, but the potential therapeutic effects of broad-spectrum inhibitors are to some extent counterbalanced by serious side effects. "Our study indicates that the development and use of HDAC1-specific inhibitors, with potentially fewer side-effects than broad-spectrum inhibitors, could be a possible approach for treating MS," says lead author Lisa Göschl, who conducted this study as part of her doctoral thesis at the Institute of Immunology and the Division of Rheumatology at MedUni Vienna. "However, a few more detailed studies are still required to clarify that," adds Ellmeier.
Service: Journal of Autoimmunity
„A T-cell specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis.“ L. Göschl, T. Pregelj, P. Hamminger, M. Bonelli, L. Andersen, N. Boucheron, A. Gülich, L. Müller, V. Saferding, I. Mufazalov, K. Hirahara, C. Seiser, P. Mathias, T. Penz, M. Schuster, C. Bock, A. Waisman, G. Steiner and W. Ellmeier. doi.org/10.1016/j.jaut.2017.09.008
Medical University Vienna
Mag. Johannes Angerer
Head of Corporate Communications and press officer
Tel: +43 (0)1 40160 - 11 501
Mobil: +43 664 800 16 11 501